You've come to the right place to understand Laboratory Services services in Europe and Emerging Markets. Here is how we can help you:
Detailed research report on Laboratory Services services with marketshare and growth rates for 22 countries and information on a further 384 (HBI Intelligence)
Database of 384 Laboratory Services service providers, including profile and major external investors (HBI Intelligence)
Merger and acquisition (M&A) intelligence showing likelihood of sale (HBI Intelligence)
News stories and interviews with Laboratory Services operators (HBI Deals and Insights)
Events that cover healthcare services globally including Laboratory Services (HBI 2020)
“A key research tool for Fresenius. Nothing else is gives such a broad, yet structured picture of all the players.”
Wolfgang Hofmann, Senior Vice president, Fresenius Medical Care
“Aetna finds the service really useful. Often insightful on business model innovation and help us in our thinking, particularly about Emerging Markets.”
Dr Sneh Khemka, Managing Director, Population Health, Aetna International
“Awesome, always on the money, full of good information, much used internally.”
CEO of one of the top five international hospital groups
“The best source of information for deals and trends in the global healthcare market.”
Mr. Stefano Ciampolini, CEO & Co-Founder, Renal Services
“A really useful tool for investors. Continually digs out interesting stories and casts light on healthcare services internationally.”
Dr Mark Wadley, Fund Manager, Visio Capital Management
“A fascinating ecosystem of data, information, and perspectives on the private healthcare market. My favourite source of information.”
Andreas Völkl, Global Marketing Manager - Outcome Studies and Collaboration, Siemens Healthineers
“I like the team at HBI, their highly focused, analytical work and their ability to bring senior people from different countries in health care together.”
Dr. Sanjeev Kanoria, Chairman, Advinia Healthcare
“May I congratulate you, very interesting and relevant content.”
Joe Ryan, CFO, Medicover
“Unique focus on private healthcare globally. Always learn something useful about sectors, companies and countries where we invest.”
Kemp Dolliver, Chief Investment Officer, Cherrystone Hill Capital Management LLC
“Really useful in keeping track of transactions across Europe and trends in healthcare services.”
Irina Stamate-Rocha, Principal, Patron Capital Advisors
“Extremely useful view of what is happening in European healthcare”
Laurent Ganem, CEO, G Square Capital
“A great site for keeping up with the healthcare sector. Its excellent search facility also means that it is easy to find older but relevant information about a given company or sector.”
Rune Aresvik, Co-owner, Vardetun
“A really valuable initiative that tracks developments across Europe. If it didn't exist, we'd have had to invent it ourselves.”
Jeremy Tasker, Head of Healthcare, Colliers International
“Gives an excellent overview of the European healthcare industry, very perceptive, written with real insight!”
Nancy Hollendoner, Industry Consultant, Senior Adviser to Hawkpoint Partners
Sector ReportLaboratory Services Sector
Updated: July 2020
Executive Summary
EXECUTIVE SUMMARY
Impact of Covid-19
We now have updates for every country’s growth forecasts for 2020 and 2021 for the diagnostic lab ector. This is a partially elective sector and there has been a strong short-term impact which we have already reported in news. A serious recession will further hit demand and leave many investors breaking their bank covenants.
Introduction
The for-profit lab market has been quickly consolidated over the past decade. Today five players take a quarter of the whole EMEA market with collective sales of €5bn. The next three add an additional €1.3m, meaning that the 2017 market share of the Big Eight was 36%.
The Big Nine are: Synlab (PE-owned), Sonic (listed), Limbach (founders), Cerba (PE), Unilabs (PE), Eurofins (listed), Biogroup-LCD (founders), amedes (PE). The first six of these are pan-European. Synlab has the widest coverage with sales in 27 European markets (plus a few emerging markets).
Aside from these, there remain a few large, family or PE-owned independents in Spain, Norway, Poland, Switzerland and Italy. It’s a question of when, more than whether, these groups will sell.
In some countries, such as Finland, Romania and the UAE, outpatient lab networks are incorporated inside healthcare networks. Private hospital groups, particularly in Germany, also include substantial lab operations. In almost all countries, labs are a discrete business strand, which doesn't perform any other business activities.
We can differentiate between four main types of national markets:
1) NHS/outsource. (the UK/Nordic) All tests, inpatient or outpatient, are typically carried out in large public hospitals and where a small for-profit sector competes for 3-10 year tenders.
2) Outpatient only. (France, Spain, Italy, Switzerland, Belgium, Romania) Traditionally tests ordered by family- or specialist-doctors operating outside hospitals have been carried out by the for-profit outpatient lab sector.
3) Outpatient + outsource. (Germany, Poland, Czechia and Slovakia) Lab groups can address the outpatient market outlined above in 2), but also win substantial outsource contracts from public sector hospitals.
4) Private pay. (Ukraine, Russia, Egypt, North Africa) In these countries citizens typically pay out of pocket for lab tests. There are no tariffs and margins tend to be very high, 35-40% is not uncommon. High co-pay means there is a growing private pay market in Italy. It is also growing across CEE.
Where we are now
The big groups grew by buying up for-profit labs set up by doctors in the 1960s to 1990s. Backed by private equity, their strategy has been to consolidate revenue and aggregate lab tests within larger, highly-automated, regional labs, capable of processing high volumes of tests at very low prices.
The result has meant relatively high EBITDA margins, although the rationalisation still continues. PE likes labs because it was the only sector of healthcare services which could be industrialised in this way.
To sell, IPO or sustain their existing share price, the lab groups have to demonstrate the ability to grow sales, and so profits. Here we look first at current growth drivers and limiters and then at opportunities and threats.
Growth drivers
1. Specialised testing
As healthcare systems across the world move towards personalised medicine and care, there is a growing demand for specialist testing. Testing an oncology patient’s genome can ensure that they are only given drugs they will respond to. Another arena is genome sequencing for the diagnosis of rare medical conditions – although by its very nature this is a low volume market.
Eurofins already has around €100m 2018 sales in genomic testing and claims it is the biggest player in the specialised testing market, with what it describes as the largest IP portfolio of pre-natal testing. Unilabs also has about €30m here. Medicover, Mehilainen, Sonic and Synlab have all made moves into genetic testing.
However, there are a number of sticking points. Samples do not degenerate as fast and so can be shipped to lower-cost markets like Beijing. We have already seen stiff competition with the prices of popular tests: some Downes tests have dropped from $1,000 to $200. On top of this much of the development work in genetics is being done in the public sector and public payors have been reluctant to approve new tests. Eurofins anticipates that France and Germany will start to reimburse some of its pre-natal tests in late 2019. However, overall the sector has grown more slowly than anticipated and profits have been lower. Competition is fierce once a market opens up.
Genetics also calls for substantial investment in R&D to develop new tests and in education to read the vast number of doctors who don’t understand the field at all. It is far from clear that the big lab groups have an appetite for the risks incurred in either of these routes.
See the report for full details on growth drivers in the laboratory sector. See the table of contents for further details on what is covered in the report.
Growth limiters and threats
1. Payor control on price and volume
These have been regular and predictable in France and Italy and intermittent and deep in Germany and Switzerland.
Often lab groups have no visibility of price cuts and certainly no control. The only plus is that institutional deadlock often stands in the way of obvious reforms. The most lucrative tests in Germany are those carried out by the 9% that have PMI. Here the tariffs have not been changed since the 1990s because such changes will need to be approved by both houses of the Bundestag.
2. Disintermediarisation
Just as an artificial kidney could destroy the entire dialysis sector, so a new point of care tests (POC) could destroy the diagnostic lab market. The well-documented failure and fraud of US-based Theranos, which claimed it could carry out a range of tests in a few minutes from a single drop of blood, terrified the industry.
Hundreds of startups around the world are working on POC testing, as are major lab suppliers like Roche, Abbott and Siemens.
Sample report pages and data
What we offer
- Instant overview of the EMEA laboratory services market and players This report gives you visibility of this important, fast-growing market across 21 countries with market data on 11 as well as detailed profiles of the Top 50 players.
- Ever green! Updated throughout your subscription As part of our HBI intelligence platform this report is updated throughout the period of your subscription. You will also receive additional news stories and interviews on laboratory services throughout the period.
- Insights on business models The report is based on in-depth interviews with many operators. The report also looks at how laboratory services players can best build customer loyalty.
- Identify national opportunities We assess opportunities at national level based on the regulatory environment and proposed reforms.
- Size markets This report enables you to swiftly see market sizes and market shares
- Save time and money This report will save you weeks researching these opaque markets and enable you to swiftly identify investment opportunities, new partners and markets.
Table of Contents
Table of Contents
EMEA overview
Datasets Size of EMEA market 2018 Marketshare of major EMEA players 2018 Comparison of market sizes 2018 Comparison of market growth rates 2016-2020
Introduction
Differentiation of four types of national markets - NHS/outsource
- Outpatient only - Outpatient + outsource - Private pay
Where we are now
Growth drivers - Specialised testing - Increasing test volumes
- Consolidation - Outsourcing
- Winning new accounts - Further rationalisation
- Growing B2C sales - Diversification beyond labs
Growth limiters and threats
- Payor control on price and volume
- Disintermediarisation
Belgium
Data sets For-profit /private market size and growth rates 2016-2020 Marketshare of major players 2018
Market description and trends.
Czech Republic
Data sets For-profit /private market size and growth rates 2016-2020 Marketshare of major players 2018
Market description and trends.
Denmark
Data sets For-profit /private market size and growth rates 2016-2020 Marketshare of major players 2018
Market description and trends.
Finland
Data sets For-profit /private market size and growth rates 2016-2020 Marketshare of major players 2018
Market description and trends.
France
Data sets For-profit /private market size and growth rates 2016-2020 Marketshare of major players 2018
Market description and trends.
Germany
Data sets For-profit /private market size and growth rates 2016-2020 Marketshare of major players 2018
Market description and trends.
Greece
Data sets For-profit /private market size and growth rates 2016-2020 Marketshare of major players 2018
Market description and trends.
Ireland
Data sets For-profit /private market size and growth rates 2016-2020 Marketshare of major players 2018
Market description and trends.
Italy
Data sets For-profit /private market size and growth rates 2016-2020 Marketshare of major players 2018
Market description and trends.
Netherlands
Data sets For-profit /private market size and growth rates 2016-2020 Marketshare of major players 2018
Market description and trends.
Norway
Data sets For-profit /private market size and growth rates 2016-2020 Marketshare of major players 2018
Market description and trends.
Poland
Data sets For-profit /private market size and growth rates 2016-2020 Marketshare of major players 2018
Market description and trends.
Portugal
Data sets For-profit /private market size and growth rates 2016-2020 Marketshare of major players 2018
Market description and trends.
Romania
Data sets For-profit /private market size and growth rates 2016-2020 Marketshare of major players 2018
Market description and trends.
Russia
Data sets For-profit /private market size and growth rates 2016-2020 Marketshare of major players 2018
Market description and trends.
South Africa
Data sets For-profit /private market size and growth rates 2016-2020 Marketshare of major players 2018
Market description and trends.
Spain
Data sets For-profit /private market size and growth rates 2016-2020 Marketshare of major players 2018
Market description and trends.
Sweden
Data sets For-profit /private market size and growth rates 2016-2020 Marketshare of major players 2018
Market description and trends.
Switzerland
Data sets For-profit /private market size and growth rates 2016-2020 Marketshare of major players 2018
Market description and trends.
Ukraine
Data sets For-profit /private market size and growth rates 2016-2020 Marketshare of major players 2018
Market description and trends.
United Kingdom
Data sets For-profit /private market size and growth rates 2016-2020 Marketshare of major players 2018
Market description and trends.
Laboratory Services News & Interviews
Our indepth stories dig deep and cover profit multiples, revenue, EBITDA and CEO thinking.
Analyst forecasts suggest that healthcare sector valuations have been largely unaffected by the crisis, with EMEA hospitals and medtech stocks now being more expensive than before the Covid outbreak, both on an EBITDA and PE multiples basis....
UK lab group Viapath has been nationalised, after Guy's and St Thomas' and King's College Hospital NHS Foundation Trusts bought out its private sector partner Serco following the loss of a £2.25bn outsourcing contract in which Synlab remains the preferred bidder...
A v-shaped recovery, new markets, new customers, new entrants, new technology and the ear of big government: the HBI 2020 diagnostics panel discussion reveals new opportunities....
Regulatory body Public Health England (PHE) has ordered telehealth player Babylon to stop selling B2C antibody tests until it has established their accuracy. Supplier Abbott has already said that the test is not suitable for home sample collection but players ...
Will Covid-19 be a game changer for the lab sector? The prospect of big government contracts and a massive, unserved B2C market is drawing new players into the diagnostic lab sector. Could they have a permanent impact?...
Pan-European lab group Synlab has issued over twice the amount of bond debt it was targeting in response to an low take-up of its bond-to-loan offer....
We talk to two of the world's largest investors in emerging market health care about Covid's likely impact. Despite so far much lower death rates, the initial effect on health care operators has been worse than in Europe. Covid is set to destroy several motors f...
Database of 384 Laboratory Services service providers
HBI has built a unique database of the Top 3,700 operators globally in health care services. As part of this, we have identified the top 384 Laboratory Services operators in Europe and will soon add the major players in Emerging Markets.
Profiles include revenue/sales data as well as EBITDA and other profit margins where known. They also cover private equity ownership with dates and mergers and acquisitions.
Mergers & Acquisition (M&A) Intelligence
Our deal pipeline shows how likely all private equity and some privately companies are to sell based on algorithms and journalistic know-how.
HBI 2020 – the only CEO-level conference to cover healthcare services globally
HBI 2020 – the only CEO-level conference to cover healthcare services globally
In 2019 this event brought together 700 delegates from over 40 countries. Over 60% are CEO level and they included 150 specialist investors in health care services. HBI 2020 includes a diagnostics session on opportunities and challenges, with a penal of operator CEOs from the laboratory and imaging sector.
Other sessions look at trends in the investment and merger and acquisition, digital health and telehealth.
Contact us in the UK on 0207 183 3779 for more information.
Stay connected for rolling updates and resources
Healthcare Business International users cookies to improve the functionality, performance, and effectiveness of our communications. Detailed information on the use of cookies is provided in our Cookies Policy. By continuing to use this site, or by clicking "I agree" you consent to the use of cookies.OkCookies Policy
